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157 Long-term impact of fungi on pediatric cystic ﬁbrosis lung
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Background and Objectives: Fungi, particularly Aspergillus and Candida species,
are increasingly found in cystic ﬁbrosis (CF) airway ﬂuids. However, their as-
sociation with other CF pathogens, medications and lung function, especially in
CF children, remains elusive. We analyzed the relationship of fungal colonization
to microbiological and clinical parameters of pediatric CF patients.
Methods and Results: Fungal colonization and long-term clinical parameters
like BMI and lung function were retrospectively studied in over 500 CF patients.
Colonization was deﬁned based on Chotirmall et al. (Chest 2010). Candida
albicans (CA) was the most prevalent fungus detected in CF airway ﬂuids, followed
by C. non-albicans > Aspergillus fumigatus (AF) > A. non-fumigatus species. We
found an association between fungal colonization and (among other parameters)
bacterial co-colonization, lung function, BMI and antibiotic therapy.
Conclusion: This study suggests that colonization with CA or AF is affected by
bacterial co-colonization and may modulate the disease severity already in pediatric
CF patients.
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Objectives: Pneumocystis jirovecii is an atypical fungus that causes pneumonia in
immunocompromised patients. Its role in patients with CF is unclear. Its reported
prevalence in CF ranges from 1−22% but has never been determined in UK centres.
Here we present preliminary cross sectional data from an ongoing study at a single
UK adult CF centre serving over 400 patients, in order to establish potential risk
and protective factors for infection.
Methods: Sputum samples were obtained from randomly selected CF patients
and sent for routine microbiology and Pneumocystis PCR assay. Symptom scores,
spirometry and inﬂammatory markers were measured and prophylactic and recent
antibiotic therapy data recorded.
Results: To date, 36 patients have been recruited. The mean age was
29.9±10.6 years, mean % predicted FEV1 52.1±17.0%. Chronic infecting organ-
isms included P. aeruginosa (64% of patients), S. aureus (44%), B. cepacia com-
plex (17%), Ralstonia spp. (6%) and M. abscessus (6%). Prophylactic azithromycin
was taken by 28 (78%) of patients, 9 patients 25%) had received co-trimoxazole
in the previous 3 months. Only 3 patients (8%) were neither on prophylactic
azithromycin nor received co-trimoxazole in the past 3 months. 1 subject had a
weakly positive PCR, 2 subjects’ samples were inhibitory for PCR and the remaining
33 subjects had negative PCR results.
Conclusion: Current patient numbers are small but preliminary results suggest
that Pneumocystis jirovecii is not an important infecting pathogen in our cohort of
patients. This may be due to frequent use co-trimoxaxole for pulmonary exacerba-
tions and high prevalence of prophylactic azithromycin at our centre compared to
published studies.
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Background: A. xylosoxidans is increasingly isolated from CF sputa. Few data on
A. xylosoxidans genotype comparison between CF patients exist.
Methods:We isolated and genotyped a total of 46 A. xylosoxidans isolates, cultured
from the sputum of 12 CF patients at the Ghent University Hospital, over a time
span of one year. Genotyping was carried out by means of McRAPD and a total
of 13 different genotypes were established.
Results: Eight patients harboured isolates of only one genotype, 3 patients har-
boured 2 genotypes, and one patient harboured 3 genotypes. Two clusters were
demonstrated, cluster 1 with four patients and cluster 2 with two patients. The one
patient with 3 genotypes, harboured one isolate with a unique genotype, two isolates
belonging to cluster 1 and four isolates belonging to cluster 2. Overall, ﬁve out of
12 patients shared identical A. xylosoxidans isolates.
Conclusion: Nearly half of our patients shared a A. xylosoxidans genotype with
one or more other patients. These results indicate possible interpatient transmission
or acquisition from a common (environmental?) source.
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Objectives: The Mycobacterium abscessus complex is an emerging group of
pathogens in CF, which may cause cross infection. Here we present results from
molecular proﬁling of M. abscessus complex isolates from patients attending a
single UK adult CF centre.
Methods: Isolates were from 12 patients who yielded 1 or more positive sputum
cultures for M. abscessus complex between January 2010 and August 2013. Isolates
were identiﬁed to subspecies level using hsp65-rpoB concatenated sequence cluster
analysis. Variable Number Tandem Repeat (VNTR) analysis was used to compare
these isolates and determine whether 2 or more patients were infected with the
same strain.
Results: 11 isolates were identiﬁed as M. abscessus subsp. abscessus. VNTR
analysis demonstrated 2 clusters of 6 and 2 patients carrying the same strains
of M. abscessus subsp. abscessus, both of which have also been isolated from
CF patients from other UK hospitals. Isolates from the remaining 3 patients were
unique. 1 additional isolate was identiﬁed as M. abscessus subsp. bolletii. No clear
epidemiological connection between patients within each cluster at our centre has
been identiﬁed to date.
Conclusion: These results provide further evidence that some strains of M. absces-
sus complex may be isolated from multiple CF patients. However, there were no
clear epidemiological connections between patients within clusters at our centre.
The same strains have been isolated from patients at different UK CF centres.
Further studies are required to determine the mode of acquisition of infection with
these strains, and whether there is a common environmental source of infection or
cross infection between patients.
